socalTECH

SEPTEMBER 20, 2010

In a blog post , Brisco said that the firm decided to become a private firm again, because it would be a "good deal" for shareholders, and also said it could become "even more focused" on long-term growth. Internet Brands had gone public just three years ago.

Internet Brands 190

Internet Brands Westlake Village Woodland Hills Beverly Hills 190

Xconomy

JULY 22, 2016

And in other Amgen news, the Thousand Oaks, CA, company filed for FDA approval of osteoporosis drug romosuzumab. Meanwhile Amgen and Allergan posted positive results from a Phase 3 trial of their own biosimilar, a copycat version of the breast cancer drug trastuzumab (Herceptin).

Startup 40

Startup San Diego News Thousand Oaks 40

Xconomy

AUGUST 5, 2016

Adicet raised $51 million earlier this year… Amgen (NASDAQ: AMGN ) of Thousand Oaks, CA, is paying $40 million immediately for rights to ADXS-NEO , a preclinical cancer treatment from Princeton, NJ-based Advaxis (NASDAQ: ADXS ). Regeneron is paying $25 million upfront.

News 40

News Thousand Oaks Pricing Report 40

Xconomy

JUNE 10, 2016

—On the positive side, Thousand Oaks, CA-based Amgen (NASDAQ: AMGN ) released an overview of Phase 2 data that showed its migraine prevention drug, erenumab, is keeping pace with rival drugs in a heated race to market.

Incubator 67

Incubator Thousand Oaks Screening Pricing 67

Xconomy

SEPTEMBER 30, 2016

—Amgen (NASDAQ: AMGN ), of Thousand Oaks, CA, and partner Novartis released positive results from the first Phase 3 trial of erenumab , one of a group of drugs being developed to prevent migraines , not just lessen their impact when they happen.

Avalon 40

Avalon Thousand Oaks Study Startup 40

Xconomy

AUGUST 26, 2016

—Amgen (NASDAQ: AMGN ) of Thousand Oaks, CA, said that the FDA rejected its drug etelcalcetide (Parasbiv) , a treatment for patients with an excess of damaging hormone release because of chronic kidney disease.

Pricing 40

Pricing Thousand Oaks Startup Research 40